AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 6.23 |
Market Cap | 442.75M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.57 |
PE Ratio (ttm) | -3.96 |
Forward PE | n/a |
Analyst | Buy |
Ask | 6.25 |
Volume | 3,403,422 |
Avg. Volume (20D) | 3,251,354 |
Open | 6.78 |
Previous Close | 6.78 |
Day's Range | 6.19 - 6.82 |
52-Week Range | 5.28 - 14.84 |
Beta | undefined |
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica...
Analyst Forecast
According to 8 analyst ratings, the average rating for ALT stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 221.29% from the latest price.
Next Earnings Release
Analysts project revenue of $620, reflecting a -98.32% YoY shrinking and earnings per share of -0.34, making a 3.03% increase YoY.
2 months ago · seekingalpha.com
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive EdgeResults from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expec...
2 months ago · seekingalpha.com
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver HealthAltimmune, Inc.'s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obe...